印度品牌价值基金会（IBEF）：2025印度制药行业研究报告（英文版）-三个皮匠报告

1、For updated information,please visit www.ibef.orgNovember 2025Pharmaceuticals2Executive Summary3Advantage India 4Market Overview 6Recent Trends and Strategies13Growth Drivers17Opportunities 26Key Industry Contacts28Appendix30Table of Contents3Executive summarySource:News Articles,Make in India,Press

2、 Information Bureau,Bain&Co,EY3.Among fastest growing industriesIn August 2025,the Indian pharmaceutical industry logged a healthy growth rate of 8.7%,with volumesincreasing modestly by 1.2%.Indias pharmaceutical industry has maintained a robust annual growth rate of over 10%for the past five years(

3、2020-25),supported by rising healthcare needs and export demand.The government has set ambitious target to boost the medical devices industry in India,aiming to elevate itfrom its current Rs.1,02,564 crore(US$12 billion)in 2023-24 valuation to Rs.4,27,350 crore(US$50 billion)by 2030.India is emergin

4、g as a key player in the global pharmaceutical supply chain,with its CRDMO industry set todouble to Rs.1,21,282 crore(US$14 billion)by 2028,says Macquarie.1.Leading pharma producerAccordingtoBain&Co,theIndianPharmaceuticalmarketstoodatRs.4,71,295 crore(US$55 billion)in 2025and is expected to grow to

5、 Rs.10,28,280-11,13,970 crore(US$120-130 billion)by2030.India,recognised as the pharmacy of theworld,suppliesoneinfivegenericmedicines globally and has risen fromseventh place in 2019 to third in globalexport volume.543212.One of the highest exportsIndiasdrugsandpharmaceuticals exports stood atRs.2,

6、59,658 crore(US$30.38billion)in FY25 and Rs.2,43,119crore(US$27.82 billion)in FY24.As of May 2025,India is thelargestsupplierofgenericmedicines providing 20%of theworlds supply and a key player inaffordable vaccines.5.Robust growth in biotech industryIndias Bioeconomy has boomed from Rs.85,690 crore

印度品牌价值基金会（IBEF）：2025印度制药行业研究报告（英文版）（33页）.pdf

相关报告